Zacks: Brokerages Expect argenx SE – (ARGX) Will Post Earnings of -$0.59 Per Share
Brokerages expect argenx SE – (NASDAQ:ARGX) to announce earnings per share of ($0.59) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for argenx’s earnings. The highest EPS estimate is ($0.52) and the lowest is ($0.72). The firm is scheduled to report its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that argenx will report full year earnings of ($2.62) per share for the current year, with EPS estimates ranging from ($2.90) to ($2.38). For the next financial year, analysts anticipate that the business will post earnings of ($3.61) per share, with EPS estimates ranging from ($4.16) to ($3.20). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that cover argenx.
A number of equities research analysts have commented on the company. Wedbush increased their price target on argenx from $93.00 to $114.00 and gave the company an “outperform” rating in a research note on Monday, June 25th. Nomura initiated coverage on argenx in a research note on Friday, June 29th. They issued a “buy” rating and a $161.00 price target for the company. Piper Jaffray Companies restated an “overweight” rating and issued a $130.00 price objective on shares of argenx in a research note on Thursday, June 7th. Cowen restated a “buy” rating on shares of argenx in a research note on Thursday, June 14th. Finally, JMP Securities raised their price objective on argenx from $93.00 to $130.00 and gave the stock a “positive” rating in a research note on Monday, June 18th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $122.83.
A number of hedge funds have recently made changes to their positions in ARGX. Aperio Group LLC purchased a new position in argenx during the first quarter valued at approximately $268,000. US Bancorp DE purchased a new position in argenx during the first quarter valued at approximately $598,000. BB Biotech AG purchased a new position in argenx during the first quarter valued at approximately $31,920,000. Northern Trust Corp purchased a new position in argenx during the first quarter valued at approximately $896,000. Finally, Dimensional Fund Advisors LP purchased a new position in argenx during the first quarter valued at approximately $498,000. Institutional investors own 52.84% of the company’s stock.
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.